rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CTMX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      CytomX at Jefferies Global Healthcare Conference: EpCAM bet gains traction
      18h agoInvesting.comCTMXJEF
      CytomX to receive $5M from Regeneron for cancer drug milestone (CTMX:NASDAQ)
      Nov 18Seeking AlphaCTMXREGN
      CytomX Therapeutics: Competitors Impress, Now Its Cytomx's Time To Shine
      Nov 13Seeking AlphaCTMX
      CytomX at guggenheim healthcare conference: varseta-m gains traction
      Nov 9Investing.comCTMX
      CytomX (CTMX) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Nov 6The Globe and MailCTMX
      CytomX Therapeutics Q3 Earnings Call Highlights
      Nov 6Yahoo FinanceCTMX
      CytomX Therapeutics Q3 2026 Earnings Call Transcript
      Nov 5BenzingaCTMX
      CytomX Therapeutics Inc earnings missed by $0.02, revenue fell short of estimates
      Nov 5Investing.comCTMX
      CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates
      Nov 5Yahoo FinanceCTMX
      CytomX Therapeutics: Q3 Earnings Snapshot
      Nov 5Yahoo FinanceCTMX
      CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update
      Nov 5Yahoo FinanceCTMX
      CytomX: Trading Near Cash Value While Varseta-M Heads Toward Pivotal Trials (NASDAQ:CTMX)

      CytomX Therapeutics earns a Buy rating on strong Varseta-M colorectal cancer data, cash runway, and upside potential. Learn more about CTMX stock here.

      Nov 5Seeking AlphaCTMX
      CytomX Therapeutics to Present at Upcoming November Investor Conferences
      Nov 2Yahoo FinanceCTMX
      CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026

      SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 5, 2026, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and

      Oct 29Yahoo FinanceCTMX
      CytomX CEO Sean McCarthy sells $461,906 in stock
      Oct 17Investing.comCTMX
      Cantor Fitzgerald reiterates Overweight on CytomX stock, $12 target
      Oct 13Investing.comCTMX
      Analysts’ Top Healthcare Picks: AbbVie (ABBV), CytomX Therapeutics (CTMX)

      Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailCTMX
      CytomX at Morgan Stanley conference: late-line crc push gains focus
      Sep 14Investing.comCTMXMS
      CytomX Therapeutics, Inc. (CTMX) Presents at Wells Fargo 21st Annual Healthcare Conference - Slideshow
      Sep 10Seeking AlphaCTMXWFC
      CytomX at cantor healthcare conference: pipeline gains, safety test ahead
      Sep 9Investing.comCTMX
      CytomX at Wells Fargo conference: epcam bet and cash strength
      Sep 8Investing.comCTMXWFC
      CytomX Therapeutics to Present at Upcoming September Investor Conferences
      Sep 1Yahoo FinanceCTMX
      FDA grants fast track status to CytomX’s colorectal cancer drug
      Aug 27Investing.comCTMX
      CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)

      - Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in 1H 2027 - SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Varseta-M fo

      Aug 27Yahoo FinanceCTMX

      This is the newest page. Registered accounts read further back.